<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02402309</url>
  </required_header>
  <id_info>
    <org_study_id>NS-003</org_study_id>
    <nct_id>NCT02402309</nct_id>
  </id_info>
  <brief_title>A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)</brief_title>
  <official_title>Phase II Study of the Safety, Pharmacokinetics, and Exploratory Activity of Once Daily (QD) Topical Application of NS2 Cream to Treat Ichthyosis in Subjects With Sjögren-Larsson Syndrome (SLS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aldeyra Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aldeyra Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, vehicle-controlled, parallel-group study
      designed to evaluate the safety, PK, and exploratory activity of topically-applied NS2
      dermatologic cream administered once-daily (QD) to subjects with ichthyosis secondary to
      Sjögren- Larsson Syndrome (SLS).

      NS2 is expected to trap fatty aldehydes that are pathogenic in SLS patients, and thereby
      diminish the lipid-aldehyde adduct formation that likely results in ichthyosis associated
      with SLS, and potentially reduce the mild dermal inflammation characteristic of SLS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a measure of Safety and Tolerability</measure>
    <time_frame>Week 8</time_frame>
    <description>As this is an early-stage safety, tolerability and exploratory activity study, no specific endpoint(s) are designated as primary or secondary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1, Day 2, Week 4, Week 8</time_frame>
    <description>Determination of single and repeat-dose PK profile of 1% NS2 topically administered to the skin.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory measurement of clinical presentation of ichthyosis pre and post-treatment</measure>
    <time_frame>Day 1, Week 4, Week 8</time_frame>
    <description>Change from baseline in intensity of ichthyosis symptoms in the treatment area pre and post-treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory measurement of disease related biomarkers pre and post-treatment</measure>
    <time_frame>Day 1, Week 4, Week 8</time_frame>
    <description>Change from baseline in pre and post-treatment biomarkers.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Sjögren-Larsson Syndrome</condition>
  <arm_group>
    <arm_group_label>Active topical NS2 1% dermatologic cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NS2 1% topical cream for dermal application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical vehicle dermatologic</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle placebo for dermal application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active topical NS2 1% dermatologic cream</intervention_name>
    <arm_group_label>Active topical NS2 1% dermatologic cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle placebo 0.0% NS2 dermatologic cream</intervention_name>
    <arm_group_label>Topical vehicle dermatologic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genetically-confirmed diagnosis of SLS

          -  Active ichthyosis on the lower extremities that is determined to be at least moderate
             severity

        Exclusion Criteria:

          -  Evidence of an active infection

          -  Currently receiving immunosuppressive therapy, including intermittent or low-dose
             corticosteroids and is not able or willing to suspend from 2 weeks before and during
             the study

          -  Currently receiving systemic or topical retinoids, other topically applied drugs, or
             other supplements that could interfere with dermatologic examination findings

          -  Received an investigational systemic or topically administered drug within 30 days
             before screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William B. Rizzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center - Department of Dermatology</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric and General Dermatology</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2015</study_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sjögren-Larsson Syndrome</keyword>
  <keyword>SLS</keyword>
  <keyword>Ichthyosis</keyword>
  <keyword>FALDH Deficiency</keyword>
  <keyword>Neuro-ichthyosis</keyword>
  <keyword>Fatty Alcohol:NAD+ Oxidoreductase Deficiency</keyword>
  <keyword>Fatty Aldehyde Dehydrogenase Deficiency Disease</keyword>
  <keyword>Congenital Icthyosis Mental Retardation Spasticity Syndrome</keyword>
  <keyword>Spastic Neurologic Disorder</keyword>
  <keyword>Oligophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Ichthyosis</mesh_term>
    <mesh_term>Sjogren-Larsson Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

